BPC-157: What the Research Actually Shows About Gut Healing and Tissue Repair

BPC-157, short for Body Protection Compound-157, is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a sequence found in human gastric juice, and it has attracted significant attention in the peptide research community for its reported effects on gastrointestinal healing and connective tissue repair. However, the evidence base requires careful scrutiny. This overview from the Peptide Register examines what the published literature actually demonstrates, where the gaps remain, and why the distinction between animal and human data matters.

What Is BPC-157 and Where Does It Come From?

BPC-157 is a partial sequence of a larger protein known as BPC, which has been isolated from human gastric juice. BPC-157 is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice. The synthetic version used in research does not occur naturally in this isolated form; it is produced in the laboratory to study the biological activities attributed to the parent compound. Researchers have investigated BPC-157 since the early 1990s, with the majority of published work originating from a single research group at the University of Zagreb in Croatia. Understanding how peptides differ from larger proteins and hormones provides useful context for interpreting these findings.

Animal Study Evidence: Gut and Tissue Repair

The bulk of BPC-157 research consists of animal studies, primarily in rats. BPC-157 animal studies have reported accelerated healing of gastric ulcers, intestinal anastomoses, and inflammatory bowel lesions in rat models. In these models, researchers have observed effects including faster closure of surgically induced gastric ulcers, improved healing of severed tendons, and reduced inflammation in experimentally induced colitis. Some studies have also reported protective effects against NSAID-induced gut damage and alcohol-related gastric lesions.

Beyond the gastrointestinal tract, animal research has explored BPC-157 in the context of tendon, ligament, muscle, and bone healing. Rat studies have suggested that BPC-157 may promote angiogenesis, the formation of new blood vessels, which is a key step in tissue repair. BPC-157 has shown angiogenic properties in rat models, which researchers have proposed as a potential mechanism underlying its tissue repair effects. Additional animal work has examined effects on the nitric oxide system, the dopaminergic system, and interactions with growth factor pathways.

It is important to note that the majority of BPC-157 animal studies originate from the same Croatian research group led by Predrag Sikiric. The majority of published BPC-157 research originates from a single research group at the University of Zagreb, limiting independent replication. Independent replication by other laboratories remains limited, which is a significant caveat when evaluating the strength of this evidence. For guidance on interpreting these kinds of study limitations, see our guide on how to read peptide research.

The Human Evidence Gap

Despite decades of animal research, no peer-reviewed, published human randomized controlled trials for BPC-157 exist in the indexed medical literature as of mid-2025. No published human randomized controlled trials for BPC-157 appear in the indexed medical literature as of mid-2025. This is a substantial gap. Some clinical trial registrations have appeared on databases such as ClinicalTrials.gov, including a Phase II trial for inflammatory bowel disease, but published results from completed human studies remain absent from the peer-reviewed record.

This absence of human data means that all reported effects, including gut healing, tendon repair, and anti-inflammatory activity, remain confined to preclinical evidence. Translating animal findings to humans is notoriously unreliable; many compounds that show efficacy in rodent models fail to demonstrate the same effects in human trials. BPC-157's reported effects on gut healing and tissue repair remain confined entirely to preclinical animal data as of 2025. Long-term safety data in humans is entirely lacking.

Regulatory Status and Access

BPC-157 is not approved by the FDA for any medical indication. BPC-157 is not approved by the FDA, TGA, or EMA for any therapeutic indication in humans. Similarly, it is not approved by the TGA in Australia or the EMA in Europe. In the United States, the FDA placed BPC-157 on its Category 1 list, which has implications for compounding pharmacies. In Australia, peptides such as BPC-157 fall under scheduling restrictions; our overview of peptide regulation across jurisdictions covers this in more detail.

BPC-157 circulates widely on the grey market, where product quality, purity, and accurate labelling cannot be verified. The Peptide Register maintains a grey market monitoring section to help researchers and clinicians understand the risks associated with unregulated sources.

Proposed Mechanisms of Action

Researchers have proposed several mechanisms through which BPC-157 may exert its observed effects in animal models. These include upregulation of growth factor receptors (particularly VEGF and EGF pathways), modulation of nitric oxide synthesis, interaction with the dopaminergic system, and effects on FAK-paxillin signaling in tendon fibroblasts. BPC-157 has been proposed to act through VEGF upregulation, nitric oxide modulation, and growth factor receptor pathways. However, these mechanistic proposals are largely derived from the same animal studies noted above and have not been confirmed through independent human pharmacological research.

Summary

BPC-157 remains one of the most discussed peptides in the research and wellness communities, but the evidence base has significant limitations. Animal data is extensive but concentrated within a single research group. Human clinical trial data is absent. No regulatory body has approved BPC-157 for therapeutic use. The Peptide Register catalogues BPC-157 alongside hundreds of other peptides in our peptide database, providing structured profiles of mechanism, evidence, and regulatory status for independent reference.

Researchers and clinicians should weigh the promising but preliminary animal findings against the complete absence of published human efficacy and safety data before drawing any conclusions about BPC-157's potential applications.